⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17854862 | 0.85 | — | — | |
| SCHEMBL14749865 | 0.84 | — | — | |
| SCHEMBL2697202 | 0.82 | — | — | |
| SCHEMBL14749862 | 0.82 | ALDH1A1 (0.32) | — | |
| SCHEMBL13502735 | 0.82 | — | — | |
| SCHEMBL21690220 | 0.77 | — | — | |
| SCHEMBL12056793 | 0.76 | EPHX1 (0.30) | — | |
| SCHEMBL14749857 | 0.74 | ALDH1A1 (0.33) | — | |
| SCHEMBL17282321 | 0.70 | — | — | |
| SCHEMBL25973602 | 0.69 | MEN1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399297-A1 | Novel Glutamine Analogs | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2023-12-14 | — | — | US | disclosed |
| US-20230355599-A1 | BIOMARKERS FOR CBL, AND COMPOSITIONS AND METHODS FOR THEIR USE | NURIX THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230355599-A1 | BIOMARKERS FOR CBL, AND COMPOSITIONS AND METHODS FOR THEIR USE | NURIX THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230150991-A1 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | NURIX THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230150991-A1 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | NURIX THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230146782-A1 | DEOXYCHOLIC ACID COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | HUANG, QIANG (CN) | 2023-05-11 | — | — | US | disclosed |
| US-11236111-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210053961-A1 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | NURIX THERAPEUTICS, INC. | 2021-02-25 | — | — | US | disclosed |
| US-20200377519-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-12-03 | — | — | US | disclosed |
| US-10017508-B2 | Nitrogenated heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-07-10 | — | — | US | disclosed |
| US-7262186-B2 | Substituted pyrazolo[3,4-d] pyrimidinones as a mitotic kinesin inhibitor | MERCK & CO., INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-7244723-B2 | Substituted furopyrimidinones as a mitotic kinesin inhibitors | MERCK & CO., INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244723-B2 | Substituted furopyrimidinones as a mitotic kinesin inhibitors | MERCK & CO., INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070149536-A1 | Inhibitors of Akt activity | MERCK SHARP & DOHME CORP. | 2007-06-28 | — | — | US | disclosed |
| US-20070142388-A1 | Inhibitors of Akt activity | MERCK SHARP & DOHME CORP. | 2007-06-21 | — | — | US | disclosed |
| US-20070129309-A1 | Conjugates useful in the treatment of prostate cancer | BRADY STEPHEN F | 2007-06-07 | — | — | US | disclosed |
| US-7223738-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20070082906-A1 | Inhibitors of akt activity | MERCK SHARP & DOHME CORP. | 2007-04-12 | — | — | US | disclosed |
| US-7192949-B2 | Substituted bicyclic pyrimidinones as a mitotic kinesin KSP inhibitors | MERCK & CO., INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-20070043001-A1 | Inhibitors of akt activity | MERCK SHARP & DOHME CORP. | 2007-02-22 | — | — | US | disclosed |